Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22213479 | 0.89 | OPRK1 (0.45) | OPRK1HTR1AADORA3HTR2CSLC6A3 | |
| SCHEMBL7924755 | 0.87 | DDB1 (0.40) | DDB1CRBN | |
| SCHEMBL12816594 | 0.84 | OPRK1 (0.45) | OPRK1HTR1AADORA3HTR2CSLC6A3 | |
| SCHEMBL12028818 | 0.82 | NPC1 (0.46) | NPC1RAB9AMEN1KMT2ANPSR1 | |
| SCHEMBL23540253 | 0.82 | OPRK1 (0.44) | OPRK1HTR1AADORA3HTR2CSLC6A3 | |
| SCHEMBL20130456 | 0.81 | DDB1 (0.42) | OPRK1HTR1AADORA3HTR2CSLC6A3 | |
| SCHEMBL12028817 | 0.80 | — | — | |
| SCHEMBL18541559 | 0.79 | NAAA (0.36) | OPRK1OPRM1AVPR1A | |
| SCHEMBL15937145 | 0.79 | CTSL (0.47) | RAB9A | |
| SCHEMBL21153687 | 0.79 | NAAA (0.38) | OPRK1HTR1AADORA3HTR2CSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210332061-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210169964-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, AND OTHER DISORDERS | INNOVIVA TRC HOLDINGS LLC | 2021-06-10 | — | — | US | disclosed |
| US-10906913-B2 | NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2021-02-02 | — | — | US | disclosed |
| US-10316041-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190077807-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20180179217-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-06-28 | — | — | US | disclosed |
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-05-10 | — | — | US | disclosed |
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-05-10 | — | — | US | disclosed |
| US-9802946-B2 | NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802946-B2 | NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150105364-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY (US) | 2015-04-16 | — | — | US | disclosed |
| WO-2014120786-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120800-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120800-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20130053325-A1 | Secondary Structure Stabilized NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053325-A1 | Secondary Structure Stabilized NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-28 | — | — | US | disclosed |
| US-20110306586-A1 | NMDA Receptor Modulators and Uses Thereof | NAUREX, INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306586-A1 | NMDA Receptor Modulators and Uses Thereof | NAUREX, INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011100585-A1 | SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF | MOSKAL JOSEPH (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2010033757-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077807-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | OPRK1 19/4885HTR1A 248/4885ADORA3 404/4885 |
| US-20210169964-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, AND OTHER DISORDERS | GRIN2A, GRIN3A, GRIN1 | OPRK1 431/4885HTR1A 44/4885ADORA3 182/4885 |
| US-10316041-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | OPRK1 30/4885HTR1A 127/4885ADORA3 799/4885 |
| US-20130053325-A1 | Secondary Structure Stabilized NMDA Receptor Modulators and Uses Thereof | GRIN2A, GRIN1, GRIN3A | OPRK1 21/4885HTR1A 297/4885ADORA3 593/4885 |
| US-20150105364-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | OPRK1 19/4885HTR1A 248/4885ADORA3 404/4885 |
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | OPRK1 30/4885HTR1A 127/4885ADORA3 799/4885 |
| US-20180179217-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | OPRK1 30/4885HTR1A 127/4885ADORA3 799/4885 |
| US-20210332061-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | OPRK1 19/4885HTR1A 248/4885ADORA3 404/4885 |
| US-20110306586-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | OPRK1 19/4885HTR1A 248/4885ADORA3 404/4885 |
| US-10906913-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | OPRK1 19/4885HTR1A 248/4885ADORA3 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.